Clinical Trials

Advanced Solid Tumors

NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Phase 3 Completed

252 enrolled

Ovarian Neoplasms

NCT04517357 2025-02-24

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Phase 2 Completed

100 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

93 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

496 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04228601 2024-08-16

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Phase 1/2 Completed

39 enrolled

Gastrointestinal

Advanced Pancreatic Cancer

NCT04300114 2024-03-28

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Phase 3 Terminated

5 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04718740 2023-08-14

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

33 enrolled

Ovarian Neoplasms

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04108676 2022-07-29

Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects

16 enrolled

Advanced Solid Tumor

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

98 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03509636 2022-07-01

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

113 enrolled

Ovarian Neoplasms

NCT05349409 2022-06-30

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Phase 2 Unknown

212 enrolled

Advanced Solid Tumors

NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Phase 3 Unknown

690 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3 Unknown

474 enrolled

Breast

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

NCT02747342 2020-07-21

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

33 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT04193319 2019-12-10

Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects

20 enrolled

Advanced Cancer

NCT02759666 2019-09-19

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

30 enrolled

Tumor-Agnostic

Neoplasms

NCT02575651 2019-06-17

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

79 enrolled

Ovarian Neoplasms

NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Phase 1 Unknown

24 enrolled

Gastrointestinal

Recurrence, Stomach Neoplasms

NCT03062982 2017-02-24

Food-Effect and Metabolism Study in Healthy Subjects

16 enrolled